Clinical Trial

Study to Use Oral Losartan to Decrease the Risk of Postoperative Scarring Following (ACL) Reconstruction

Not Yet Recruiting Phase 4
View on ClinicalTrials.gov →
Summary
The purpose of this study to investigate the effect of using losartan (a blood pressure lowering drug with anti-scarring properties) on preventing primary postoperative arthrofibrosis (formation of abnormal scar tissue) in the knees in participants undergoing anterior cruciate ligament (ACL) repair surgery of their knee.
Protocol Amendment History 2 amendments
This ClinicalTrials.gov record has been amended 2 times since 2025-08-14; most recent amendment 2025-12-09.
Trial Details
NCT Number NCT07135687
Lead Sponsor Rush University Medical Center
Collaborators: Arthroscopy Association of North America
Conditions ACL Injury, ACL Reconstruction, Scar Formation
Enrollment 144 participants
Start Date 2026-08
Primary Completion 2028-10 (estimated)
Study Completion 2028-12 (estimated)
Updated on ClinicalTrials.gov 2025-12-15